Skip to content
Close
SEARCH
CONTACT US
CONTACT US

OUR SERVICES

We take a personalized and integrated approach to help our clients position their pipelines and companies for success offering a full range of development and commercialization services.

VIEW ALL SERVICES
PHASES
DISCOVERY
Uncover breakthrough
innovations during the drug
discovery phase.
CLINICAL DEVELOPMENT
Advance through clinical
development and health
authority review with confidence.
ALL STAGES
Benefit from our expertise
across all phases
of drug development.
PRECLINICAL
Navigate the critical
preclinical testing phase
with expert guidance.
COMMERCIALIZATION
Successfully bring your
product to market with
our commercialization support.
ALL SERVICES
Access comprehensive
services for every stage
of product development.

ABOUT US

We are Halloran, a life science consulting firm, partnering to enrich your product development and business growth. We propel your organization further; positively impacting the health and wellbeing of patients around the world.

LEARN MORE ABOUT US
EXPERTISE WITH PERSONALITY
OUR FOUNDER
Discover the visionary
leader driving Halloran's
success and innovation.
STRATEGIC PARTNERS
Meet our trusted
strategic partners who
enhance our capabilities.
WHY HALLORAN?
Explore the unique reasons
why clients choose
Halloran for their needs.
OUR TEAM
Get to know the dedicated
professionals who make
up the Halloran team.
CAREERS
Join our dynamic team
and advance your
career with Halloran.
LEARN MORE
Find out more about
Halloran's comprehensive
services and expertise.
Sheila GwizdakApr 7, 2025 9:34:32 AM1 min read

Impacts of ICH GCP E6 (R3) Webinar

Join Halloran Consulting Group for a compelling discussion on how to future-proof your clinical quality processes and navigate global regulatory expectations as you transition to ICH GCP E6 (R3)  compliance in a rapidly evolving digital environment.


The ICH GCP E6 (R3) guideline represents a transformative global shift in Good Clinical Practice (GCP), aligning with the evolving expectations of regulatory agencies such as the FDA, EMA, and PMDA. With a strong emphasis on risk-based quality management (RBQM), data integrity, and technology-driven oversight, this update challenges sponsors, CROs, and sites to redefine their approach to compliance, quality, and clinical trial execution in an increasingly digital-first environment.
 
In this insight-driven webinar, our industry experts will demystify the key changes introduced in GCP E6 (R3) and examine how regulatory authorities worldwide are adapting to digital transformation in clinical trial oversight. 
 

Viewers will gain global perspectives and actionable strategies on:

  • Key updates in GCP E6 (R3) and their implications for sponsors, CROs, and sites
  • The evolving role of risk-based quality management (RBQM) in clinical trial execution and regulatory expectations
  • Harnessing AI, automation, and digital tools to optimize compliance, oversight and operational efficiency
  • Best practices for ensuring data integrity and risk-based monitoring in a globally regulated digital environment
  • Strategic steps to implement digital-first quality management approaches that comply with international regulatory requirements


 
Sheila Gwizdak

RELATED ARTICLES

Elizabeth BodiApr 14, 2025 5:52:43 PM1 min read

Key Update on Guideline for Good Clinical Practice E6(R3)

January 6, 2025: ICH assembly agreed that ICH GCP E6 R3 Principles and Annex 1 could be adopted to advance the topics in R2, ...
Start Reading
Carolina Ahrendt, MBA, PMPApr 10, 2025 12:40:26 PM6 min read

Ticking Timeline: Tips for Effective Product Development Timelines

Once a biotech or pharmaceutical company defines their product development objectives including business strategy, global ...
Start Reading
Kanchana IyerApr 3, 2025 10:30:00 AM3 min read

Navigating Drug, Biologic and Medical Device Regulatory Strategies

Contributing Author: Mamta Puri-Lechner In a recent webinar, Kanchana Iyer and Mamta Puri-Lechner, Senior Consultants at ...
Start Reading